Accelerate Diagnostics

Accelerate Diagnostics PP&E per Employee

Delisted

The PP&E per Employee of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 72,514.02 USD. In the previous year, PP&E per Employee was 73,822.43 USD — a change of -1.77% (lower).

PP&E per Employee

72,514.02USD

YoY

-1.77%

Last updated:

PP&E per Employee of Accelerate Diagnostics is 2022 72,514.02 USD. PP&E per Employee of Accelerate Diagnostics was 2021 73,822.43 USD. It decreases by -1.77% lower compared to the previous year.

The Accelerate Diagnostics PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
46,878.50 USD
Jan 1, 2016
39,794.39 USD
Jan 1, 2017
45,700.93 USD
Jan 1, 2018
68,252.34 USD
Jan 1, 2019
73,878.50 USD
Jan 1, 2020
57,336.45 USD
Jan 1, 2021
73,822.43 USD
Jan 1, 2022
72,514.02 USD
The Accelerate Diagnostics PP&E per Employee history
YEARPP&E per EmployeeYoY
72,514.02USD-1.77%
73,822.43USD+28.75%
57,336.45USD-22.39%
73,878.50USD+8.24%
68,252.34USD+49.35%
45,700.93USD+14.84%
39,794.39USD-15.11%
46,878.50USD+97.79%
23,700.93USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

PP&E per Employee of Accelerate Diagnostics is 72,514.02 USD in 2022.

PP&E per Employee of Accelerate Diagnostics changed from 73,822.43 USD to 72,514.02 USD, representing a -1.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics